MX2019011629A - Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. - Google Patents
Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad.Info
- Publication number
- MX2019011629A MX2019011629A MX2019011629A MX2019011629A MX2019011629A MX 2019011629 A MX2019011629 A MX 2019011629A MX 2019011629 A MX2019011629 A MX 2019011629A MX 2019011629 A MX2019011629 A MX 2019011629A MX 2019011629 A MX2019011629 A MX 2019011629A
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- nr1h4
- modulating compounds
- compounds
- fxr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a compuestos que se unen al receptor NR1H4 (FXR) y actúan como agonistas de FXR. La invención además se refiere al uso de los compuestos para la preparación de un medicamento para el tratamiento de enfermedades y/o trastornos a través de la unión a dicho receptor nuclear por dichos compuestos y a un proceso para la síntesis de dichos compuestos (1). Z es seleccionado de (a), (b), (c), o (d). (ver Fórmulas).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161507153P | 2011-07-13 | 2011-07-13 | |
EP11005722A EP2545964A1 (en) | 2011-07-13 | 2011-07-13 | Novel FXR (NR1H4) binding and activity modulating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011629A true MX2019011629A (es) | 2019-12-05 |
Family
ID=44513243
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000534A MX368371B (es) | 2011-07-13 | 2012-07-12 | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. |
MX2019011629A MX2019011629A (es) | 2011-07-13 | 2014-01-13 | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000534A MX368371B (es) | 2011-07-13 | 2012-07-12 | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. |
Country Status (31)
Country | Link |
---|---|
US (5) | US9139539B2 (es) |
EP (4) | EP2545964A1 (es) |
JP (2) | JP5986633B2 (es) |
KR (4) | KR101934335B1 (es) |
CN (2) | CN107252424B (es) |
AR (1) | AR087127A1 (es) |
AU (4) | AU2012283387C1 (es) |
BR (3) | BR122020008872B1 (es) |
CA (1) | CA2839357C (es) |
CY (1) | CY1117453T1 (es) |
DK (2) | DK3246070T3 (es) |
EA (1) | EA024843B1 (es) |
ES (2) | ES2632492T3 (es) |
FI (1) | FI3246070T3 (es) |
HK (2) | HK1221680A1 (es) |
HR (1) | HRP20160442T1 (es) |
HU (1) | HUE027931T2 (es) |
IL (1) | IL229944A (es) |
LT (1) | LT3246070T (es) |
ME (1) | ME02434B (es) |
MX (2) | MX368371B (es) |
MY (1) | MY161158A (es) |
PL (2) | PL2731676T3 (es) |
PT (1) | PT2987532T (es) |
RS (1) | RS54786B1 (es) |
SI (2) | SI2731676T1 (es) |
SM (1) | SMT201600169B (es) |
TW (1) | TWI439455B (es) |
UY (1) | UY34196A (es) |
WO (1) | WO2013007387A1 (es) |
ZA (1) | ZA201309521B (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
IL253437A0 (en) * | 2011-07-13 | 2017-09-28 | Gilead Sciences Inc | New compounds modulate fxr (nr1h4) activity and bind |
EA031003B1 (ru) | 2013-09-11 | 2018-10-31 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций |
ES2731602T3 (es) | 2014-09-24 | 2019-11-18 | Gilead Sciences Inc | Métodos para tratar la enfermedad hepática |
EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
CN107106555A (zh) * | 2014-12-18 | 2017-08-29 | 诺华股份有限公司 | 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用 |
MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
US9586933B2 (en) | 2014-12-23 | 2017-03-07 | Gilead Sciences, Inc. | Processes for preparing ASK1 inhibitors |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
DK3277286T3 (da) | 2015-03-31 | 2021-07-05 | Enanta Pharm Inc | Galdesydererivater som fxr/tgr5-agonister og anvendelsesmetoder deraf |
JP6430060B2 (ja) | 2015-07-06 | 2018-11-28 | ギリアード サイエンシーズ, インコーポレイテッド | Cotモジュレーターおよびその使用方法 |
WO2017128896A1 (zh) * | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
CN106995416A (zh) * | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
TW201741307A (zh) * | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Fxr調節劑及其使用方法 |
EP3423057A1 (en) | 2016-03-04 | 2019-01-09 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
AU2017248354A1 (en) | 2016-04-08 | 2018-10-04 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017201150A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
CA2968836A1 (en) * | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
EP3730487B1 (en) * | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
CN106237332A (zh) * | 2016-08-11 | 2016-12-21 | 河南大学 | 核受体fxr在肝癌干细胞靶向治疗中的应用 |
WO2018067704A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
EP3538097A1 (en) * | 2016-11-11 | 2019-09-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
CN106588804B (zh) * | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
WO2018133730A1 (zh) * | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
JP2020508316A (ja) | 2017-02-21 | 2020-03-19 | ジェンフィGenfit | Pparアゴニストとfxrアゴニストとの組合せ |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
EP4122464B1 (en) * | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
MX2019011844A (es) | 2017-04-07 | 2021-11-30 | Enanta Pharm Inc | Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato. |
CA3059883A1 (en) * | 2017-04-12 | 2018-10-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
DK3612520T3 (da) | 2017-04-12 | 2021-12-06 | Il Dong Pharma | Isoxazolderivater som kernereceptoragonister og anvendelser deraf |
JP7029583B2 (ja) | 2017-05-31 | 2022-03-04 | パナソニックIpマネジメント株式会社 | 洗濯機 |
US10495648B2 (en) | 2017-06-13 | 2019-12-03 | Gilead Sciences, Inc. | Methods of treating liver fibrosis |
CA3077273A1 (en) | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | Combination therapy comprising an acc inhibitor |
PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
WO2019089664A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
KR20200083529A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 |
WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
AU2018357878A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid X receptor modulators |
WO2019094777A1 (en) | 2017-11-13 | 2019-05-16 | Gilead Sciences, Inc. | Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CN112638473B (zh) | 2018-08-08 | 2022-06-07 | 因奥必治疗有限公司 | 用于调节类法尼醇x受体的化合物以及制备和使用所述化合物的方法 |
CN110818704B (zh) * | 2018-08-08 | 2023-08-01 | 广州市恒诺康医药科技有限公司 | 螺桥环化合物、其药物组合物及其用途 |
JP2022500392A (ja) | 2018-09-18 | 2022-01-04 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
EP4360632A2 (en) | 2019-01-15 | 2024-05-01 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
AU2020234929B2 (en) * | 2019-03-11 | 2023-09-14 | Gilead Sciences, Inc. | Formulations of a compound and uses thereof |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
WO2021133948A1 (en) | 2019-12-23 | 2021-07-01 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
AU2021240001A1 (en) * | 2020-03-18 | 2022-10-13 | Organovo, Inc. | Farnesoid X receptor agonists for the treatment of disease |
US20240043418A1 (en) | 2020-03-26 | 2024-02-08 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
JP2023520650A (ja) | 2020-03-30 | 2023-05-18 | ギリアード サイエンシーズ, インコーポレイテッド | (S)-6-(((1-(ビシクロ[1.1.1]ペンタン-1-イル)-1H-1,2,3-トリアゾール-4-イル)2-メチル-1-オキソ-1,2-ジヒドロイソキノリン-5-イル)メチル)))アミノ)8-クロロ-(ネオペンチルアミノ)キノリン-3-カルボニトリルCot阻害剤化合物の固体形態 |
US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN114656460A (zh) * | 2020-12-22 | 2022-06-24 | 江苏天士力帝益药业有限公司 | 一种新型吡嗪结构fxr激动剂、制备方法及应用 |
EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
US20220298148A1 (en) | 2021-03-11 | 2022-09-22 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
JP2024512646A (ja) | 2021-03-29 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | Khk阻害剤 |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療fxr誘發之搔癢之il-31調節劑 |
WO2023125904A1 (zh) * | 2021-12-30 | 2023-07-06 | 苏州晶云药物科技股份有限公司 | 氮杂环丁基烟酸类化合物的晶型及其制备方法 |
WO2024089582A1 (en) | 2022-10-25 | 2024-05-02 | Assia Chemical Industries Ltd. | Solid state forms of cilofexor salts |
Family Cites Families (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ193011A (en) | 1979-03-19 | 1983-03-15 | Ici Australia Ltd | Diarylamine derivatives intermediates herbicidal compositions |
EP0287959B1 (de) | 1987-04-21 | 1993-04-28 | BASF Aktiengesellschaft | p-Phenoxy-phenoxymethyl-fünfring-heteroaromaten |
JP3121061B2 (ja) | 1991-10-04 | 2000-12-25 | 塩野義製薬株式会社 | アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体 |
DE4137940A1 (de) | 1991-11-18 | 1993-05-19 | Basf Ag | 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung |
US5258551A (en) | 1991-12-18 | 1993-11-02 | Shionogi & Co., Ltd. | Process for producing α-ketoamide derivative |
AU5891494A (en) | 1993-01-29 | 1994-08-15 | Nippon Soda Co., Ltd. | Heterocyclic derivative |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
AU699272B2 (en) | 1994-08-02 | 1998-11-26 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives |
GB9501865D0 (en) | 1995-01-31 | 1995-03-22 | Merck Sharp & Dohme | Therapeutic agents |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
DE19536811A1 (de) | 1995-10-02 | 1997-04-03 | Basf Ag | Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel |
DK0880363T3 (da) | 1996-02-13 | 2003-01-20 | Searle & Co | Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger |
EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
EP1185539B1 (en) | 1999-06-11 | 2004-12-01 | Allergan, Inc. | Organosilyl compounds having nuclear hormone receptor modulating activity |
EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | isoxazole |
US20040131670A1 (en) | 2001-04-17 | 2004-07-08 | Ping Gao | Pellicle-resistant gelatin capsule |
US20040105884A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Pharmaceutical dosage form comprising a sulfite compound |
US20040105885A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Gelatin capsule exhibiting reduced cross-linking |
US20040105883A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
US7223791B2 (en) | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
EP1423113A4 (en) | 2001-08-13 | 2007-04-18 | Phenex Pharmaceuticals Ag | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS |
WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
WO2003080803A2 (en) | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
AU2003259068B2 (en) | 2002-08-09 | 2009-07-02 | Astrazeneca Ab | "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5 |
EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
WO2004046162A2 (en) | 2002-11-14 | 2004-06-03 | The Scripps Research Institute | Non-steroidal fxr agonists |
US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
US20070166710A1 (en) | 2003-03-31 | 2007-07-19 | Markus Stoffel | Methods for inhibiting adipogenesis and for treating type 2 diabetes |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2005113519A1 (en) | 2004-05-14 | 2005-12-01 | Irm Llc | Compounds and compositions as ppar modulators |
MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
EP2363129A1 (en) | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
RU2008128823A (ru) | 2005-12-15 | 2010-01-20 | Экселиксис, Инк. (Us) | Производные азепиноиндола в качестве фармацевтических средств |
ATE526318T1 (de) | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
JP5301286B2 (ja) | 2006-02-03 | 2013-09-25 | イーライ リリー アンド カンパニー | Fx受容体を調節するための化合物及び方法 |
CN101395170A (zh) * | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
EP2007759A4 (en) | 2006-04-17 | 2010-12-22 | Neuromed Pharmaceuticals Ltd | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS |
JP2009537590A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
CN101448798A (zh) * | 2006-05-24 | 2009-06-03 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
ATE465996T1 (de) | 2006-05-24 | 2010-05-15 | Lilly Co Eli | Fxr-agonisten |
ATE460403T1 (de) * | 2006-05-24 | 2010-03-15 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
AU2007265457C1 (en) | 2006-06-27 | 2012-11-29 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
WO2008005538A2 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
CN101501023A (zh) | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
WO2008013660A2 (en) | 2006-07-07 | 2008-01-31 | Biostratum, Inc. | Inhibitors of advanced glycation end products |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
US8501933B2 (en) | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
US20090105251A1 (en) | 2007-01-25 | 2009-04-23 | Benjamin Jones | Renin inhibitors |
AU2007346136B2 (en) | 2007-02-09 | 2012-10-25 | Corteva Agriscience Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
US7511149B2 (en) | 2007-02-09 | 2009-03-31 | Dow Agrosciences Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
JP5302221B2 (ja) | 2007-02-26 | 2013-10-02 | ダウ アグロサイエンシィズ エルエルシー | ある種の置換スルフィルイミン類の調製方法 |
US20100249179A1 (en) | 2007-06-13 | 2010-09-30 | Smithkline Beecham Corporation | Farnesoid X Receptor Agonists |
JP2008308448A (ja) | 2007-06-15 | 2008-12-25 | Sankyo Agro Kk | (3−硫黄原子置換フェニル)へテロアリール誘導体 |
WO2008155054A1 (en) | 2007-06-20 | 2008-12-24 | F. Hoffmann-La Roche Ag | Farnesoid-x-receptor mutants, and crystallisation thereof |
WO2009003998A2 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
EP2173174A4 (en) | 2007-07-02 | 2010-08-04 | Glaxosmithkline Llc | FARNESOID X RECEPTOR AGONISTS |
US20090197880A1 (en) | 2007-07-13 | 2009-08-06 | Genelabs Technologies, Inc. | Anti-viral compounds, compositions, and methods of use |
EP2178877A1 (en) | 2007-07-13 | 2010-04-28 | GlaxoSmithKline LLC | Anti-viral compounds, compositions, and methods of use |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
CA2694887A1 (en) | 2007-08-01 | 2009-02-05 | Henriette Husum Bak-Jensen | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
US8188080B2 (en) | 2007-10-17 | 2012-05-29 | Sanford-Burnham Medical Research Institute | VHR protein tyrosine phosphatase inhibitors, compositions and methods of use |
US20090143451A1 (en) | 2007-11-14 | 2009-06-04 | Andrews William H | Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2009140089A2 (en) | 2008-05-13 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
EP2291372A4 (en) | 2008-05-19 | 2012-04-25 | Burnham Inst Medical Research | MODULATORS OF ALKALINE PHOSPHATASE FROM DARM AND APPLICATIONS THEREOF |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
CN104530052A (zh) | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
CA2727078A1 (en) | 2008-06-23 | 2009-12-30 | Basf Se | Sulfoximinamide compounds for combating animal pests |
US20100029655A1 (en) | 2008-07-11 | 2010-02-04 | Martin Robert Leivers | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them |
EP2318381A1 (en) | 2008-08-25 | 2011-05-11 | Dow Global Technologies LLC | Process for preparing isoxazole compounds |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
CA2735886A1 (en) | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | Indazole or 4,5,6,7-tetrahydro-indazole derivatives |
KR101444988B1 (ko) | 2008-09-25 | 2014-09-26 | 에프. 호프만-라 로슈 아게 | 3-아미노-인다졸 또는 3-아미노-4,5,6,7-테트라하이드로-인다졸 유도체 |
JP2012503654A (ja) | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | 1,2,3,6−テトラヒドロアゼピノ[4,5−b]インドール−5−カルボキシレート核内受容体阻害剤 |
CA2740366A1 (en) | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
EP2393807B1 (en) | 2009-02-04 | 2013-08-14 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1 |
WO2010093191A2 (en) | 2009-02-13 | 2010-08-19 | Lg Life Sciences Ltd. | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
FR2943059A1 (fr) | 2009-03-16 | 2010-09-17 | Sanofi Aventis | Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique |
JP2012532175A (ja) | 2009-07-06 | 2012-12-13 | ビーエーエスエフ ソシエタス・ヨーロピア | 無脊椎動物系害虫防除用ピリダジン化合物 |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
EP2456308A2 (en) | 2009-07-24 | 2012-05-30 | Basf Se | Pyridine derivatives for controlling invertrebate pests |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
KR20120081119A (ko) | 2009-09-04 | 2012-07-18 | 잘리커스 파마슈티컬즈 리미티드 | 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체 |
WO2011047129A1 (en) | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
CN104592205A (zh) | 2010-03-01 | 2015-05-06 | Gtx公司 | 用于治疗癌的化合物 |
EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
WO2012058531A2 (en) | 2010-10-29 | 2012-05-03 | North Carolina State University | Modulation of response regulators by imidazole derivatives |
TWI408128B (zh) | 2010-12-03 | 2013-09-11 | Nat Univ Tsing Hua | 間-三聯苯衍生物及其在有機發光二極體之應用 |
US20130261108A1 (en) | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
US20140039007A1 (en) | 2010-12-20 | 2014-02-06 | David C. Tully | Compositions and methods for modulating farnesoid x receptors |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
DK3336097T3 (da) | 2012-06-19 | 2020-09-28 | Intercept Pharmaceuticals Inc | Fremstilling af ikke-krystallinsk obeticholsyre |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
CA2912139C (en) | 2013-05-14 | 2021-04-20 | Roberto Pellicciari | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
JP6556129B2 (ja) | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドx受容体の阻害剤及び医薬としての使用 |
EA031003B1 (ru) | 2013-09-11 | 2018-10-31 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций |
US20150082981A1 (en) | 2013-09-20 | 2015-03-26 | E I Du Pont De Nemours And Company | Capture of trifluoromethane using ionic liquids |
CN104513213A (zh) | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
WO2015065983A1 (en) | 2013-10-29 | 2015-05-07 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of gastrointestinal infections |
TR201807321T4 (tr) | 2013-11-05 | 2018-06-21 | Novartis Ag | Farnesoid x reseptörlerinin modüle edilmesi için bileşimler ve yöntemler. |
WO2015116856A2 (en) | 2014-01-29 | 2015-08-06 | City Of Hope | Farnesoid x receptor antagonists |
EP3116851B1 (en) | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogs of fexaramine and methods of making and using |
KR20160132111A (ko) | 2014-03-13 | 2016-11-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Fxr 작용제와 제조방법 및 용도 |
US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
KR20160144487A (ko) | 2014-04-14 | 2016-12-16 | 그뤼넨탈 게엠베하 | 헤테로아릴 치환된 헤테로사이클릴 설폰 |
WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
WO2015162244A1 (en) | 2014-04-25 | 2015-10-29 | Basf Se | N-acylamidine compounds |
WO2015165960A1 (en) | 2014-04-30 | 2015-11-05 | Basf Se | N-acylamidine compounds |
HUE048351T2 (hu) | 2014-05-29 | 2020-07-28 | Bar Pharmaceuticals S R L | Kolán-származékok alkalmazása FXR és TGR5/GPBAR1 mediált betegségek kezelésére és/vagy prevenciójára |
CN104045635A (zh) | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
US9855249B2 (en) | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
CN106716665B9 (zh) | 2014-10-27 | 2018-12-07 | 株式会社Lg化学 | 有机电致发光器件 |
AU2015343025A1 (en) | 2014-11-06 | 2017-06-08 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an FXR/TGR5 agonists and methods of use thereof |
MX370480B (es) | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
CN107106555A (zh) | 2014-12-18 | 2017-08-29 | 诺华股份有限公司 | 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用 |
WO2016112305A1 (en) | 2015-01-09 | 2016-07-14 | Nimbus Apollo, Inc. | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
MX2017009408A (es) | 2015-01-20 | 2017-10-02 | Merial Inc | Compuestos antihelminticos, composiciones y metodo para usar los mismos. |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
CN106146483A (zh) | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
GB201507340D0 (en) | 2015-04-29 | 2015-06-10 | Univ St Andrews | Light emitting devices and compounds |
ES2550374B1 (es) * | 2015-06-30 | 2016-09-08 | Universidad De La Rioja | Compuestos fotoprotectores análogos de MAA, procedimiento de síntesis y composición que comprende los mismos |
CN107920523A (zh) | 2015-07-13 | 2018-04-17 | 范德比尔特大学 | Orco激动剂的热挥发 |
JP6869231B2 (ja) | 2015-09-11 | 2021-05-12 | プロパジェニクス インコーポレイテッド | ex vivoでの上皮細胞の増殖 |
EA037257B1 (ru) | 2015-12-04 | 2021-02-26 | Бристол-Маерс Сквибб Компани | Новые агонисты рецептора апелина и способы применения |
TW201734002A (zh) | 2015-12-11 | 2017-10-01 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代的丙二醯胺類 |
CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
US10882871B2 (en) | 2016-01-10 | 2021-01-05 | British Columbia Cancer Agency Branch | 18/19F-labelled compounds which target the prostate specific membrane antigen |
WO2017122209A2 (en) | 2016-01-12 | 2017-07-20 | Yeda Research And Development Co. Ltd. | NF-kappaB INHIBITORS |
WO2017128896A1 (zh) | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
CN107021958A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
WO2017133521A1 (zh) | 2016-02-01 | 2017-08-10 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
CN107021957A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
TW201741307A (zh) | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Fxr調節劑及其使用方法 |
CN107224583A (zh) | 2016-03-24 | 2017-10-03 | 中美华世通生物医药科技(武汉)有限公司 | 药物组合物及其用途 |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
KR102444366B1 (ko) | 2016-06-03 | 2022-09-19 | 케모센트릭스, 인크. | 간 섬유화 치료 방법 |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
CN110177783B (zh) | 2016-08-23 | 2023-06-06 | 阿德利克斯股份有限公司 | 用于治疗代谢病状和病症的激素受体调节剂 |
US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
WO2018059314A1 (zh) | 2016-09-28 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
WO2018060075A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection |
WO2018067704A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
KR20210042421A (ko) | 2016-11-10 | 2021-04-19 | 갈메드 리서치 앤드 디벨롭먼트 리미티드 | 섬유증에 대한 치료 |
EP3538097A1 (en) | 2016-11-11 | 2019-09-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
CN106588804B (zh) | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
CN106632294A (zh) | 2016-12-15 | 2017-05-10 | 宁波百纳西药业有限公司 | 一种螺环化合物及其药物用途 |
CN106748922B (zh) | 2017-01-12 | 2019-02-01 | 中国药科大学 | 一类新型砜酸衍生物、其制备方法及其作为药物的用途 |
-
2011
- 2011-07-13 EP EP11005722A patent/EP2545964A1/en not_active Withdrawn
-
2012
- 2012-07-02 TW TW101123785A patent/TWI439455B/zh active
- 2012-07-11 AR ARP120102511A patent/AR087127A1/es active IP Right Grant
- 2012-07-12 US US14/232,118 patent/US9139539B2/en active Active
- 2012-07-12 FI FIEP17000383.4T patent/FI3246070T3/fi active
- 2012-07-12 RS RS20160266A patent/RS54786B1/sr unknown
- 2012-07-12 LT LTEP17000383.4T patent/LT3246070T/lt unknown
- 2012-07-12 PL PL12735100T patent/PL2731676T3/pl unknown
- 2012-07-12 CN CN201710308892.5A patent/CN107252424B/zh active Active
- 2012-07-12 AU AU2012283387A patent/AU2012283387C1/en active Active
- 2012-07-12 KR KR1020187013304A patent/KR101934335B1/ko active IP Right Grant
- 2012-07-12 ES ES15002478.4T patent/ES2632492T3/es active Active
- 2012-07-12 UY UY0001034196A patent/UY34196A/es active IP Right Grant
- 2012-07-12 EP EP12735100.5A patent/EP2731676B1/en active Active
- 2012-07-12 WO PCT/EP2012/002941 patent/WO2013007387A1/en active Application Filing
- 2012-07-12 CA CA2839357A patent/CA2839357C/en active Active
- 2012-07-12 MX MX2014000534A patent/MX368371B/es active IP Right Grant
- 2012-07-12 SI SI201230535A patent/SI2731676T1/sl unknown
- 2012-07-12 EP EP15002478.4A patent/EP2987532B1/en active Active
- 2012-07-12 ES ES12735100.5T patent/ES2569718T3/es active Active
- 2012-07-12 DK DK17000383.4T patent/DK3246070T3/da active
- 2012-07-12 DK DK12735100.5T patent/DK2731676T3/en active
- 2012-07-12 PT PT150024784T patent/PT2987532T/pt unknown
- 2012-07-12 PL PL15002478T patent/PL2987532T3/pl unknown
- 2012-07-12 KR KR1020177021651A patent/KR101859533B1/ko active IP Right Grant
- 2012-07-12 BR BR122020008872-9A patent/BR122020008872B1/pt active IP Right Grant
- 2012-07-12 CN CN201280033148.4A patent/CN103702719B/zh active Active
- 2012-07-12 JP JP2014519453A patent/JP5986633B2/ja active Active
- 2012-07-12 EA EA201391674A patent/EA024843B1/ru unknown
- 2012-07-12 MY MYPI2013004373A patent/MY161158A/en unknown
- 2012-07-12 BR BR112014000260-6A patent/BR112014000260B1/pt active IP Right Grant
- 2012-07-12 EP EP17000383.4A patent/EP3246070B1/en active Active
- 2012-07-12 KR KR1020147002937A patent/KR101722410B1/ko active IP Right Grant
- 2012-07-12 SI SI201230969A patent/SI2987532T1/sl unknown
- 2012-07-12 HU HUE12735100A patent/HUE027931T2/en unknown
- 2012-07-12 KR KR1020177000763A patent/KR101766323B1/ko active IP Right Grant
- 2012-07-12 ME MEP-2016-81A patent/ME02434B/me unknown
- 2012-07-12 BR BR122019026062-1A patent/BR122019026062B1/pt active IP Right Grant
-
2013
- 2013-12-17 IL IL229944A patent/IL229944A/en active IP Right Grant
- 2013-12-17 ZA ZA2013/09521A patent/ZA201309521B/en unknown
-
2014
- 2014-01-13 MX MX2019011629A patent/MX2019011629A/es unknown
- 2014-06-11 HK HK16109776.3A patent/HK1221680A1/zh unknown
- 2014-06-11 HK HK14105521.1A patent/HK1192181A1/zh unknown
-
2015
- 2015-08-12 US US14/824,971 patent/US9539244B2/en active Active
-
2016
- 2016-04-25 HR HRP20160442TT patent/HRP20160442T1/hr unknown
- 2016-04-28 CY CY20161100369T patent/CY1117453T1/el unknown
- 2016-06-10 SM SM201600169T patent/SMT201600169B/it unknown
- 2016-08-05 JP JP2016154511A patent/JP6321097B2/ja active Active
- 2016-11-29 AU AU2016265993A patent/AU2016265993B2/en active Active
- 2016-12-05 US US15/369,521 patent/US9820979B2/en active Active
-
2017
- 2017-10-13 US US15/783,530 patent/US10220027B2/en active Active
-
2018
- 2018-05-22 AU AU2018203613A patent/AU2018203613B2/en active Active
-
2019
- 2019-01-15 US US16/248,178 patent/US10485795B2/en active Active
- 2019-11-04 AU AU2019261667A patent/AU2019261667B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011629A (es) | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. | |
PH12020551959A1 (en) | Fxr (nr1h4) modulating compounds | |
NZ748641A (en) | Fxr (nr1h4) modulating compounds | |
IN2012DN00790A (es) | ||
NZ732210A (en) | Novel fxr (nr1h4) modulating compounds | |
NZ732246A (en) | Hydroxy containing fxr (nr1h4) modulating compounds | |
MX2009002274A (es) | Compuestos de enlace fxr heterociclicos. | |
MX2021008518A (es) | Compuestos que modulan fxr(nr1h4). | |
MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
EA201201541A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ | |
EA201300388A1 (ru) | Соединения замещенного бензамида | |
PH12015500211A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. | |
MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
MA32945B1 (fr) | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique | |
MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. |